CYTK Q3 2019 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-43.1% YoY

Gross Profit

-$14M-234.1% margin

Operating Income

-$24M-395.2% margin

Net Income

-$30M-488.4% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

-15.2%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$187M

Total Liabilities

$207M

Stockholders' Equity

-$20M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$11M	-43.1%
Gross Profit	-$14M	-$11M	-31.9%
Operating Income	-$24M	-$18M	-33.6%
Net Income	-$30M	-$22M	-34.3%

Revenue Segments

Research And Development

$6M100%